Dissecting the restricted mean time in favor of treatment

References

• Abdalla, S., M. E. Montez-Rath, P. S. Parfrey, and G. M. Chertow. 2016. The win ratio approach to analyzing composite outcomes: An application to the evolve trial. Contemporary Clinical Trials 48:119–124. doi:10.1016/j.cct.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Akacha, M., F. Bretz, D. Ohlssen, G. Rosenkranz, and H. Schmidli. 2017. Estimands and their role in clinical trials. Statistics in Biopharmaceutical Research 9 (3):268–271. doi:10.1080/19466315.2017.1302358.
   Web of Science ®Google Scholar
• Anker, S. D., and J. V. McMurray. 2012. Time to move on from “time-to-first”: Should all events be included in the analysis of clinical trials. European Heart Journal 33 (22):2764–2765. doi:10.1093/eurheartj/ehs277.
   PubMed Web of Science ®Google Scholar
• Armstrong, P. W., and C. M. Westerhout. 2017. Composite end points in clinical research: A time for reappraisal. Circulation 135 (23):2299–2307. doi:10.1161/CIRCULATIONAHA.117.026229.
   PubMed Web of Science ®Google Scholar
• Buyse, M. 2010. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Statistics in Medicine 29 (30):3245–3257. doi:10.1002/sim.3923.
   PubMed Web of Science ®Google Scholar
• Crowther, M. J., and P. C. Lambert. 2017. Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. Statistics in Medicine 36 (29):4719–4742. doi:10.1002/sim.7448.
   PubMed Web of Science ®Google Scholar
• Cui, Y., G. Dong, P. F. Kuan, and B. Huang. 2022. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials. Journal of Biopharmaceutical Statistics 33 (3):272–288. doi:10.1080/10543406.2022.2141769.
   PubMed Web of Science ®Google Scholar
• Dong, G., D. C. Hoaglin, B. Huang, Y. Cui, D. Wang, Y. Cheng, and M. Gamalo-Siebers. 2023. The stratified win statistics (win ratio, win odds, and net benefit). Pharmaceutical Statistics. doi:10.1002/pst.2293.
   Web of Science ®Google Scholar
• Dong, G., B. Huang, Y. -W. Chang, Y. Seifu, J. Song, and D. C. Hoaglin. 2020. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards. Pharmaceutical Statistics 19 (3):168–177. doi:10.1002/pst.1977.
   PubMed Web of Science ®Google Scholar
• Dong, G., B. Huang, J. Verbeeck, Y. Cui, J. Song, M. Gamalo-Siebers, D. Wang, D. C. Hoaglin, Y. Seifu, T. Mütze, et al. (2022). Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes. Pharmaceutical Statistics 10.1002/pst.2251.
   Google Scholar
• Dong, G., J. Qiu, D. Wang, and M. Vandemeulebroecke. 2018. The stratified win ratio. Journal of Biopharmaceutical Statistics 28 (4):778–796. doi:10.1080/10543406.2017.1397007.
   PubMed Web of Science ®Google Scholar
• Finkelstein, D. M., and D. A. Schoenfeld. 1999. Combining mortality and longitudinal measures in clinical trials. Statistics in Medicine 18 (11):1341–1354. doi:10.1002/(SICI)1097-0258(19990615)18:11<1341:AID-SIM129>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• Fleming, T. R., and D. P. Harrington. 1991. Counting Processes and Survival Analysis. Hoboken, NJ: John Wiley & Sons.
   Google Scholar
• Freemantle, N., M. Calvert, J. Wood, J. Eastaugh, and C. Griffin. 2003. Composite outcomes in randomized trials: Greater precision but with greater uncertainty. Journal of the American Medical Association 289 (19):2554–2559. doi:10.1001/jama.289.19.2554.
   PubMed Web of Science ®Google Scholar
• Kandzari, D. E., G. L. Hickey, S. J. Pocock, M. A. Weber, M. Boehm, S. A. Cohen, M. Fahy, G. Lamberti, and F. Mahfoud. 2021. Prioritised endpoints for device-based hypertension trials: The win ratio methodology. EuroIntervention: Journal of EuroPcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 16 (18):e1496–1502. doi:10.4244/EIJ-D-20-01090.
   PubMed Web of Science ®Google Scholar
• Mao, L. 2023. On restricted mean time in favor of treatment. Biometrics 79 (1):61–72. doi:10.1111/biom.13570.
   PubMed Web of Science ®Google Scholar
• Mao, L., and K. Kim. 2021. Statistical models for composite endpoints of death and non-fatal events: A review. Statistics in Biopharmaceutical Research 13 (3):260–269. doi:10.1080/19466315.2021.1927824.
   PubMed Web of Science ®Google Scholar
• Mao, L., K. Kim, and Y. Li. 2022. On recurrent-event win ratio. Statistical Methods in Medical Research 31 (6):1120–1134. doi:10.1177/09622802221084134.
   PubMed Web of Science ®Google Scholar
• Maurer, M. S., J. H. Schwartz, B. Gundapaneni, P. M. Elliott, G. Merlini, M. Waddington-Cruz, A. V. Kristen, M. Grogan, R. Witteles, T. Damy, et al. 2018. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. The New England Journal of Medicine. 379(11):1007–1016. doi:10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• McCaw, Z. R., G. Yin, and L. -J. Wei. 2019. Using the restricted mean survival time difference as an alternative to the hazard ratio for analyzing clinical cardiovascular studies. Circulation 140 (17):1366–1368. doi:10.1161/CIRCULATIONAHA.119.040680.
   PubMed Web of Science ®Google Scholar
• Moertel, C. G., T. R. Fleming, J. S. Macdonald, D. G. Haller, J. A. Laurie, P. J. Goodman, J. S. Ungerleider, W. A. Emerson, D. C. Tormey, J. H. Glick, et al. 1990. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. The New England Journal of Medicine. 322(6):352–358. doi:10.1056/NEJM199002083220602.
   PubMed Web of Science ®Google Scholar
• Oakes, D. 1989. Bivariate survival models induced by frailties. Journal of the American Statistical Association 84 (406):487–493. doi:10.1080/01621459.1989.10478795.
   Web of Science ®Google Scholar
• Oakes, D. 2016. On the win-ratio statistic in clinical trials with multiple types of event. Biometrika 103 (3):742–745. doi:10.1093/biomet/asw026.
   Web of Science ®Google Scholar
• O’Connor, C. M., D. J. Whellan, K. L. Lee, S. J. Keteyian, L. S. Cooper, S. J. Ellis, E. S. Leifer, W. E. Kraus, D. W. Kitzman, J. A. Blumenthal, et al. 2009. Efficacy and safety of exercise training in patients with chronic heart failure: Hf-action randomized controlled trial. Journal of the American Medical Association. 301(14):1439–1450. doi:10.1001/jama.2009.454.
   PubMed Web of Science ®Google Scholar
• Pocock, S., C. Ariti, T. Collier, and D. Wang. 2012. The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European Heart Journal 33 (2):176–182. doi:10.1093/eurheartj/ehr352.
   PubMed Web of Science ®Google Scholar
• Redfors, B., J. Gregson, A. Crowley, T. McAndrew, O. Ben-Yehuda, G. W. Stone, and S. J. Pocock. 2020. The win ratio approach for composite endpoints: Practical guidance based on previous experience. European Heart Journal 41 (46):4391–4399. doi:10.1093/eurheartj/ehaa665.
   PubMed Web of Science ®Google Scholar
• Royston, P., and M. K. Parmar. 2011. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine 30 (19):2409–2421. doi:10.1002/sim.4274.
   PubMed Web of Science ®Google Scholar
• Seifu, Y., S. Mt-Isa, K. Duke, M. Gamalo-Siebers, W. Wang, G. Dong, and J. Kolassa. 2022. Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (aei) and win-statistics. Journal of Biopharmaceutical Statistics 1–12. doi:10.1080/10543406.2022.2153202.
   PubMed Web of Science ®Google Scholar
• Tian, L., H. Fu, S. J. Ruberg, H. Uno, and L. -J. Wei. 2018. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biometrics 74 (2):694–702. doi:10.1111/biom.12770.
   PubMed Web of Science ®Google Scholar
• Tian, L., H. Jin, H. Uno, Y. Lu, B. Huang, K. M. Anderson, and L. Wei. 2020. On the empirical choice of the time window for restricted mean survival time. Biometrics 76 (4):1157–1166. doi:10.1111/biom.13237.
   PubMed Web of Science ®Google Scholar
• Tsiatis, A. 2006. Semiparametric Theory and Missing Data. New York: Springer.
   Google Scholar
• Uno, H., B. Claggett, L. Tian, E. Inoue, P. Gallo, T. Miyata, D. Schrag, M. Takeuchi, Y. Uyama, L. Zhao, et al. 2014. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. Journal of Clinical Oncology. 32(22):2380. doi:10.1200/JCO.2014.55.2208.
   PubMed Web of Science ®Google Scholar
• Vardeny, O., K. Kim, J. A. Udell, J. Joseph, A. S. Desai, M. E. Farkouh, S. M. Hegde, A. F. Hernandez, A. McGeer, H. K. Talbot, et al. 2021. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: A randomized clinical trial. JAMA. 325(1):39–49. doi:10.1001/jama.2020.23649.
   PubMed Web of Science ®Google Scholar